How Thymosin β4 Fights Liver Scarring by Blocking the MAPK/NF-κB Inflammatory Pathway | Research

The takeaway

Thymosin β4 overexpression reduced liver fibrosis in mice and inhibited stellate cell activation by blocking ROS production and MAPK/NF-κB pathway activation.

Tβ4 overexpression inhibited fibrosis via MAPK/NF-κB
Both pharmacological confirmation (MAPK activator reversed protection, inhibitor mimicked it) in vitro and in vivo proved that thymosin β4 works specifically through the ROS/MAPK/NF-κB cascade to reduce liver scarring.

What the researchers found

Thymosin β4 (Tβ4) was downregulated in bile duct ligation (BDL) fibrotic mice and TGF-β1-induced LX-2 hepatic stellate cells. Tβ4 overexpression via lentiviral vectors: inhibited liver fibrosis in BDL mice (confirmed by HE and Masson staining), suppressed stellate cell migration and proliferation in TGF-β1-induced LX-2 cells, reduced ROS production, and blocked MAPK/NF-κB pathway activation (confirmed by reduced p-p38, p-ERK, p-JNK, and nuclear p65). Adding a MAPK activator (U-46619) reversed Tβ4's protective effects, while a MAPK inhibitor (SB203580) mimicked them — both in vitro and in vivo.

Why it matters

Liver fibrosis progresses to cirrhosis and liver failure, and no approved anti-fibrotic drugs exist for the liver. Thymosin β4 is already known to be safe in humans from wound healing studies, so identifying its anti-fibrotic mechanism could accelerate clinical development. The specific pathway identified (ROS → MAPK/NF-κB) provides clear molecular targets for therapeutic intervention.

How the study worked

Liver fibrosis mouse models were created by bile duct ligation (BDL) and validated by histological staining. TGF-β1-induced LX-2 hepatic stellate cells served as the in vitro model. Tβ4-overexpressing lentiviral vectors were used for gain-of-function studies. Outcomes measured: RT-qPCR for Tβ4 expression, Western blot for HSC activation markers and MAPK/NF-κB proteins, DCFH-DA for ROS, CCK-8 for proliferation, flow cytometry for cell cycle, Transwell for migration, and immunofluorescence for nuclear p65. MAPK activator and inhibitor experiments confirmed the pathway in both cells and BDL mice.

What this study cannot tell us

The BDL model creates biliary-type fibrosis, which differs from the more common metabolic-associated and viral fibrosis in humans. Lentiviral overexpression achieves supraphysiological Tβ4 levels that may not reflect achievable therapeutic concentrations. The study focused on one signaling pathway, but fibrosis involves multiple interconnected pathways. LX-2 cells are an immortalized hepatic stellate cell line that may not fully represent primary cells. No dose-response relationship for Tβ4 was established.

How to read the evidence

This is a well-designed preclinical study with both in vitro and in vivo models, gain-of-function experiments, and pharmacological pathway confirmation. The dual confirmation (activator reversal + inhibitor mimicry) in both cell culture and mice is methodologically strong. However, findings are limited to animal models.

When this study was published

Published in 2023, this study adds mechanistic clarity to the growing body of evidence for thymosin β4 as a multi-organ protective peptide.

The bigger picture

Thymosin β4 continues to demonstrate therapeutic potential across multiple organ systems — wound healing, cardiac repair, neuroprotection, and now liver fibrosis. This study adds mechanistic depth by identifying the specific signaling cascade (ROS → MAPK → NF-κB) through which Tβ4 operates in the liver. Combined with Tβ4's established safety profile from clinical wound healing studies, this strengthens the case for testing it as an anti-fibrotic agent.

Questions still open

Can exogenous thymosin β4 administration (injection or infusion) achieve sufficient liver concentrations to reduce fibrosis in humans?
Does this anti-fibrotic mechanism extend to metabolic-associated fatty liver disease (MAFLD), the most common cause of liver fibrosis?
Could thymosin β4 be combined with other anti-fibrotic strategies for additive or synergistic effects?

Common questions

Can thymosin β4 treat liver fibrosis?

In this mouse study, increasing thymosin β4 levels significantly reduced liver fibrosis by blocking the inflammatory pathway that activates scar-producing cells. Since thymosin β4 has already been tested safely in humans for wound healing, it could potentially be repurposed for liver fibrosis — but human liver fibrosis trials are still needed.

How does thymosin β4 protect the liver from scarring?

Liver fibrosis happens when hepatic stellate cells become activated and produce excess scar tissue. Thymosin β4 blocks this process by reducing harmful reactive oxygen species (ROS), which in turn prevents activation of the MAPK/NF-κB inflammatory signaling cascade. Without this cascade running, stellate cells don't activate, don't proliferate, and don't produce scar tissue.

Read the original research

Mechanism of thymosin β4 in ameliorating liver fibrosis via the MAPK/NF-κB pathway.

Journal of biochemical and molecular toxicology, 37(7), e23338

View on PubMed ↗Publisher’s paper ↗

Citation

Wang, Zilin; Zhang, Ya; Wang, Yinghui; Mou, Qiuju; Ren, Tingting; Zhu, Lili. (2023). Mechanism of thymosin β4 in ameliorating liver fibrosis via the MAPK/NF-κB pathway.. Journal of biochemical and molecular toxicology, 37(7), e23338. https://doi.org/10.1002/jbt.23338